Doxorubicin treatment also induces p21 expression in neuroblastoma cell lines in which the p53/MDM2/p14ARF pathway is not altered, while cell lines with mutated TP53 are not capable of raising p21 levels above their basal levels [61]. The gene discussed is CDKN2A; the disease is neuroblastoma.